# Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

> **NCT02601209** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 151 (actual)

## Conditions studied

- High Grade Sarcoma
- Metastatic Leiomyosarcoma
- Metastatic Malignant Peripheral Nerve Sheath Tumor
- Metastatic Synovial Sarcoma
- Metastatic Undifferentiated Pleomorphic Sarcoma
- Metastatic Unresectable Sarcoma
- Myxofibrosarcoma
- Recurrent Leiomyosarcoma
- Recurrent Malignant Peripheral Nerve Sheath Tumor
- Recurrent Synovial Sarcoma
- Recurrent Undifferentiated Pleomorphic Sarcoma
- Stage III Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8
- Unresectable Leiomyosarcoma

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Pazopanib Hydrochloride
- **DRUG:** Sapanisertib

## Key facts

- **NCT ID:** NCT02601209
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11-30
- **Primary completion:** 2018-12-07
- **Final completion:** 2022-07-11
- **Target enrollment:** 151 (ACTUAL)
- **Why stopped:** Interim monitoring
- **Last updated:** 2022-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02601209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02601209, "Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02601209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*